keyword
MENU ▼
Read by QxMD icon Read
search

statin and meta

keyword
https://www.readbyqxmd.com/read/29789212/fibrates-in-primary-prevention-of-cardiovascular-disease-comments-on-the-results-of-a-systematic-review-of-the-cochrane-collaboration
#1
Angel Brea, Jesús Millán, Juan F Ascaso, Mariano Blasco, Angel Díaz, Antonio Hernández-Mijares, Teresa Mantilla, Juan C Pedro-Botet, Xavier Pintó
Fibrates are drugs that reduce triglycerides, elevate high-density lipoproteins, as well as decrease small, dense LDL particles. The results of a study have recently been published by the Cochrane Collaboration on fibrates efficacy and safety in the primary prevention of cardiovascular disease. This study includes a systematic review and a meta-analysis of 6 studies (16,135 patients) that evaluated the clinical benefits of fibrates compared to placebo use or other lipid-lowering drugs. This review showed evidence of a protective effect of the fibrates compared with placebo as regards a reduction 16% of a compound objective of death due to cardiovascular disease, non-fatal myocardial infarction, or non-fatal cerebrovascular accident (NNT: 112), and that reduce coronary morbidity and mortality by 21% (NNT: 125)...
May 19, 2018: Clínica e Investigación en Arteriosclerosis
https://www.readbyqxmd.com/read/29785580/a-comprehensive-review-and-meta-analysis-of-risk-factors-for-statin-induced-myopathy
#2
REVIEW
Khoa A Nguyen, Lang Li, Deshun Lu, Aida Yazdanparast, Lei Wang, Rolf P Kreutz, Elizabeth C Whipple, Titus K Schleyer
PURPOSE: To aid prescribers in assessing a patient's risk for statin-induced myopathy (SIM), we performed a comprehensive review of currently known risk factors and calculated aggregated odds ratios for each risk factor through a meta-analysis. METHODS: This meta-analysis was done through four phases: (1) Identification of the relevant primary literature; (2) abstract screening using inclusion and exclusion criteria; (3) detailed review and data extraction; and (4) synthesis and statistical analysis...
May 22, 2018: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29776337/should-statin-guidelines-consider-patient-preferences-eliciting-preferences-of-benefit-and-harm-outcomes-of-statins-for-primary-prevention-of-cardiovascular-disease-in-the-sub-saharan-african-and-european-contexts
#3
Henock G Yebyo, Hélène E Aschmann, Tsung Yu, Milo A Puhan
BACKGROUND: Patient preferences are key parameters to evaluate benefit-harm balance of statins for primary prevention but they are not readily available to guideline developers and decision makers. Our study aimed to elicit patient preferences for benefit and harm outcomes related to use of statins for primary cardiovascular disease prevention and to examine how the preferences differ across economically and socio-culturally different environments. METHODS: We conducted preference-eliciting surveys using best-worst scaling designed with a balanced incomplete-block design (BIBD) on 13 statins-related outcomes on 220 people in Ethiopia and Switzerland...
May 18, 2018: BMC Cardiovascular Disorders
https://www.readbyqxmd.com/read/29771699/the-optimal-time-of-day-for-statin-administration-a-review-of-current-evidence
#4
Kamal Awad, Maciej Banach
PURPOSE OF REVIEW: In humans, cholesterol biosynthesis varies diurnally, reaching its peak at night. Therefore, choosing the time of statin administration is critical because of their different half-lives. Dose timing becomes more important in patients with polypharmacy because it might affect their adherence to the statin therapy. RECENT FINDINGS: Herein, we narratively summarized the available clinical studies (n = 17) and meta-analyses (n = 2) that compared the morning with the evening dose of statins in terms of safety and efficacy, with special focus on their low-density lipoprotein-lowering effects...
May 15, 2018: Current Opinion in Lipidology
https://www.readbyqxmd.com/read/29766679/comparison-of-the-effects-of-ezetimibe-statin-combination-therapy-on-major-adverse-cardiovascular-events-in-patients-with-and-without-diabetes-a-meta-analysis
#5
Namki Hong, Yong Ho Lee, Kenichi Tsujita, Jorge A Gonzalez, Christopher M Kramer, Tomas Kovarnik, George N Kouvelos, Hiromichi Suzuki, Kyungdo Han, Chan Joo Lee, Sung Ha Park, Byung Wan Lee, Bong Soo Cha, Eun Seok Kang
BACKGROUND: Ezetimibe-statin combination therapy has been found to reduce low density lipoprotein cholesterol levels and the risk of major adverse cardiovascular events (MACEs) in large trials. We sought to examine the differential effect of ezetimibe on MACEs when added to statins according to the presence of diabetes. METHODS: Randomized clinical trials with a sample size of at least 50 participants and at least 24 weeks of follow-up that compared ezetimibe-statin combination therapy with a statin- or placebo-controlled arm and reported at least one MACE, stratified by diabetes status, were included in the meta-analysis and meta-regression...
May 4, 2018: Endocrinology and Metabolism
https://www.readbyqxmd.com/read/29752194/sex-specific-relevance-of-diabetes-to-occlusive-vascular-and-other-mortality-a-collaborative-meta-analysis-of-individual-data-from-980-793-adults-from-68-prospective-studies
#6
(no author information available yet)
BACKGROUND: Several studies have shown that diabetes confers a higher relative risk of vascular mortality among women than among men, but whether this increased relative risk in women exists across age groups and within defined levels of other risk factors is uncertain. We aimed to determine whether differences in established risk factors, such as blood pressure, BMI, smoking, and cholesterol, explain the higher relative risks of vascular mortality among women than among men. METHODS: In our meta-analysis, we obtained individual participant-level data from studies included in the Prospective Studies Collaboration and the Asia Pacific Cohort Studies Collaboration that had obtained baseline information on age, sex, diabetes, total cholesterol, blood pressure, tobacco use, height, and weight...
May 8, 2018: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29741972/effects-of-perioperative-statins-on-patient-outcomes-after-noncardiac-surgery-a-meta-analysis
#7
Baoxin Ma, Jingwu Sun, Shuling Diao, Bo Zheng, Hua Li
BACKGROUND: Cardiovascular complications are strongly correlated with a higher risk of mortality during follow-up after noncardiac surgery. However, controversy remains regarding whether perioperative administration of hydroxymethylglutaryl-CoA reductase inhibitors (statins) has a beneficial effect on patient outcomes. OBJECTIVE: We performed a meta-analysis to validate the hypothesis that perioperative statins improve patient outcomes after noncardiac surgery. METHODS: Electronic databases (PubMed, Web of Science, EMBASE, and the Cochrane Library) were searched for randomized controlled trials (RCTs) published up to 10 November 2017...
May 9, 2018: Annals of Medicine
https://www.readbyqxmd.com/read/29737304/therapeutic-effects-of-statins-drugs-use-and-continuous-nursing-on-patients-with-chronic-obstructive-pulmonary-disease-and-the-influence-of-life-quality
#8
Ju Weina, Liu Yanhua, Wang Jian, Shao Yan
Chronic obstructive pulmonary disease (COPD) is able to be treated and delayed. Many interventions include smoking cessation and daily maintenance of drug therapy. In clinical practice, although respiratory physicians have given optimal drug treatment to patients, there is no treatment for etiological factors in these treatments, and they have little effect on the long-term prognosis of COPD. Therefore, this paper puts forward a method of continuing care. Through Meta analysis of the therapeutic effects of statins, it is shown that statins have a positive impact on the treatment of chronic obstructive pulmonary disease...
May 2018: Pakistan Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/29735471/therapeutic-effects-of-statins-drugs-use-and-continuous-nursing-on-patients-with-chronic-obstructive-pulmonary-disease-and-the-influence-of-life-quality
#9
Ju Weina, Liu Yanhua, Wang Jian, Shao Yan
Chronic obstructive pulmonary disease (COPD) is able to be treated and delayed. Many interventions include smoking cessation and daily maintenance of drug therapy. In clinical practice, although respiratory physicians have given optimal drug treatment to patients, there is no treatment for etiological factors in these treatments, and they have little effect on the long-term prognosis of COPD. Therefore, this paper puts forward a method of continuing care. Through Meta analysis of the therapeutic effects of statins, it is shown that statins have a positive impact on the treatment of chronic obstructive pulmonary disease...
May 2018: Pakistan Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/29733433/statin-therapy-on-glycemic-control-in-type-2-diabetic-patients-a-network-meta-analysis
#10
J Y Cui, R R Zhou, S Han, T S Wang, L Q Wang, X H Xie
WHAT IS KNOWN AND OBJECTIVE: Statins are the cornerstone of primary and secondary prevention of cardiovascular diseases (CVDs) and are effective for the prevention of vascular events in diabetic patients. Diabetes mellitus is an important risk factor for CVDs .The majority of patients with diabetes mellitus benefits from statin therapy. According to the recent clinical guidelines of the American College of Cardiology and the American Heart Association, moderate-intensity or high-intensity statin therapy should be used as the primary prevention for individuals with diabetes mellitus, aged between 40 and 75 years and with low-density lipoprotein cholesterol (LDL-C) from 70 to 189 mg/dL...
May 7, 2018: Journal of Clinical Pharmacy and Therapeutics
https://www.readbyqxmd.com/read/29726857/clinical-inquiries-does-niacin-decrease-cardiovascular-morbidity-and-mortality-in-cvd-patients
#11
Peter Lazzopina, Anne Mounsey, Lara Handler
No. Niacin doesn't reduce cardiovascular disease (CVD) morbidity or mortality in patients with established disease (strength of recommendation [SOR]: A, meta-analyses of randomized controlled trials [RCTs] and subsequent large RCTs). Niacin may be considered as monotherapy for patients intolerant of statins (SOR: B, one well-done RCT).
May 2018: Journal of Family Practice
https://www.readbyqxmd.com/read/29723231/long-term-effect-of-statins-on-the-risk-of-new-onset-osteoporosis-a-nationwide-population-based-cohort-study
#12
Tsung-Kun Lin, Pesus Chou, Ching-Heng Lin, Yi-Jen Hung, Gwo-Ping Jong
BACKGROUND: Several observational cohort and meta-analytical studies in humans have shown that statin users have a lower risk of fractures or greater bone mineral densities (BMD) than nonusers. However, some studies including randomized clinical trials have the opposite results, particularly in Asian populations. OBJECTIVE: This study investigates the impacts of statins on new-onset osteoporosis in Taiwan. METHODS: In a nationwide retrospective population-based cohort study, 45,342 subjects aged between 50-90 years having received statin therapy (statin-users) since January 1 2001, and observed through December 31 2013 were selected from the National Health Insurance Research Database of Taiwan...
2018: PloS One
https://www.readbyqxmd.com/read/29722274/statins-use-and-cancer-an-update
#13
Martyna Zaleska, Olga Mozenska, Jacek Bil
After initial concerns regarding the association of statins with increased incidences of cancer and elevated cancer-related mortality, there are now plenty of data on the antitumor, cytostatic and cytotoxic effectiveness of this class of drugs. Here, we present a short review of possible mechanisms of antineoplastic activity obtained from preclinical research and the influence of statins on cancer treatment. In the second part of the article, we focus on the most recent data from observational clinical trials, as well as meta-analyses regarding cancer incidence and mortality in patients treated with statins...
May 3, 2018: Future Oncology
https://www.readbyqxmd.com/read/29721321/machine-learning-of-big-data-in-gaining-insight-into-successful-treatment-of-hypertension
#14
Gideon Koren, Galia Nordon, Kira Radinsky, Varda Shalev
Despite effective medications, rates of uncontrolled hypertension remain high. Treatment protocols are largely based on randomized trials and meta-analyses of these studies. The objective of this study was to test the utility of machine learning of big data in gaining insight into the treatment of hypertension. We applied machine learning techniques such as decision trees and neural networks, to identify determinants that contribute to the success of hypertension drug treatment on a large set of patients. We also identified concomitant drugs not considered to have antihypertensive activity, which may contribute to lowering blood pressure (BP) control...
June 2018: Pharmacology Research & Perspectives
https://www.readbyqxmd.com/read/29705799/modeling-statin-induced-reductions-of-cardiovascular-events-in-primary-prevention-a-voyager-meta-analysis
#15
Björn W Karlson, Stephen J Nicholls, Pia Lundman, Philip J Barter, Michael K Palmer
OBJECTIVE: We used individual patient data from the VOYAGER database to estimate cardiovascular (CV) risk reduction with commonly used high-intensity statins. METHODS: In patients with known atherosclerotic CV disease (ASCVD) treated with high-intensity statin therapy (n = 6,735), the predicted risk reduction was estimated using the Cholesterol Treatment Trialists' Collaboration meta-analysis, which determined risk reduction per 38.7 mg/dL statin-mediated reduction in low-density lipoprotein cholesterol...
April 27, 2018: Cardiology
https://www.readbyqxmd.com/read/29703846/-lpa-variants-are-associated-with-residual-cardiovascular-risk-in-patients-receiving-statins
#16
Wei-Qi Wei, Xiaohui Li, Qiping Feng, Michiaki Kubo, Iftikhar J Kullo, Peggy L Peissig, Elizabeth W Karlson, Gail P Jarvik, Ming Ta Michael Lee, Ning Shang, Eric A Larson, Todd Edwards, Christian Shaffer, Jonathan D Mosley, Shiro Maeda, Momoko Horikoshi, Marylyn Ritchie, Marc S Williams, Eric B Larson, David R Crosslin, Sarah T Bland, Jennifer A Pacheco, Laura J Rasmussen-Torvik, David Cronkite, George Hripcsak, Nancy J Cox, Russell A Wilke, C Michael Stein, Jerome I Rotter, Yukihide Momozawa, Dan M Roden, Ronald M Krauss, Joshua C Denny
Background -Coronary heart disease (CHD) is a leading cause of death globally. Although therapy with HMG-CoA reductase inhibitors (statins) decreases circulating levels of low-density lipoprotein cholesterol (LDL-C) and the incidence of CHD, additional events occur despite statin therapy in some individuals. The genetic determinants of this residual cardiovascular risk remain unknown. Methods -We performed a two-stage genome-wide association study (GWAS) of CHD events during statin therapy. We first identified 3,099 cases who experienced CHD events (defined as acute myocardial infarction or the need for coronary revascularization) during statin therapy and 7,681 controls without CHD events during comparable intensity and duration of statin therapy from four sites in the Electronic Medical Records and Genomics (eMERGE) Network...
April 27, 2018: Circulation
https://www.readbyqxmd.com/read/29693013/effect-of-stains-on-ldl-reduction-and-liver-safety-a-systematic-review-and-meta-analysis
#17
REVIEW
Xiao Liang, Qin He, Qinghua Zhao
Background and Aim: Statin is a class of medications used to decrease low-density lipoprotein cholesterol level to prevent cardiovascular disease. However, the risk of hepatic damage caused by statin therapy is still controversial. We conducted a systematic review and meta-analysis summarizing the existing evidence of the effect of statin therapy on incidence of liver injury to clarify whether statin therapy could lead to liver function test abnormalities. Methods: We searched the Cochrane Library, PubMed, and Embase database for the relevant studies update till Jan...
2018: BioMed Research International
https://www.readbyqxmd.com/read/29677301/association-between-baseline-ldl-c-level-and-total-and-cardiovascular-mortality-after-ldl-c-lowering-a-systematic-review-and-meta-analysis
#18
REVIEW
Eliano P Navarese, Jennifer G Robinson, Mariusz Kowalewski, Michalina Kolodziejczak, Felicita Andreotti, Kevin Bliden, Udaya Tantry, Jacek Kubica, Paolo Raggi, Paul A Gurbel
Importance: Effects on specific fatal and nonfatal end points appear to vary for low-density lipoprotein cholesterol (LDL-C)-lowering drug trials. Objective: To evaluate whether baseline LDL-C level is associated with total and cardiovascular mortality risk reductions. Data Sourcesand Study Selection: Electronic databases (Cochrane, MEDLINE, EMBASE, TCTMD, ClinicalTrials.gov, major congress proceedings) were searched through February 2, 2018, to identify randomized clinical trials of statins, ezetimibe, and PCSK9-inhibiting monoclonal antibodies...
April 17, 2018: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/29667439/what-is-the-impact-of-the-2017-cochrane-systematic-review-and-meta-analysis-that-evaluated-the-use-of-pcsk9-inhibitors-for-lowering-cardiovascular-disease-and-mortality
#19
Mohamed A Jalloh, Eric J Ip, Shadi Doroudgar
In 2017, Schmidt et al. conducted a Cochrane systematic review and meta-analysis to evaluate the effect of using proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors to reduce low-density-lipoprotein- cholesterol (LDL-C) and cardiovascular disease (CVD). The Cochrane review was a systematic review and meta-analysis of 20 randomized, double-blinded trials that compared the use of PCSK9 inhibitors with statins/ezetimibe, ezetimibe, or placebo for a treatment duration of at least 24 weeks. The use of PCSK9 inhibitors lowered the risk for CVD (OR 0...
April 18, 2018: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29661588/impact-of-metabolic-diseases-drugs-and-dietary-factors-on-prostate-cancer-risk-recurrence-and-survival-a-systematic-review-by-the-european-association-of-urology-section-of-oncological-urology
#20
REVIEW
Riccardo Campi, Sabine D Brookman-May, Jose Daniel Subiela Henríquez, Bülent Akdoğan, Maurizio Brausi, Tobias Klatte, Johan F Langenhuijsen, Estefania Linares-Espinos, Martin Marszalek, Morgan Roupret, Christian G Stief, Alessandro Volpe, Andrea Minervini, Oscar Rodriguez-Faba
CONTEXT: To date, established risk factors for prostate cancer (PCa) are limited to age, race, family history, and certain genetic polymorphisms. Despite great research efforts, available evidence on potentially modifiable risk factors is conflicting. Moreover, most studies on PCa risk factors did not consider the impact of prostate-specific antigen (PSA) testing on PCa diagnosis. OBJECTIVE: To provide a detailed overview of the latest evidence on the role of metabolic diseases, drugs, and dietary factors for risk of PCa incidence, recurrence, and survival in men exposed to PSA testing...
April 13, 2018: European Urology Focus
keyword
keyword
45848
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"